Ashley Chan

With a significant change happening in the Medicare space in early 2025, patients with cancer eligible for Medicare may see its benefits soon.

Black patients may be more affected by certain side effects from Talvey compared with White patients with multiple myeloma, an expert told CURE®.

Baseline ctDNA presence was associated with larger tumor size and higher residual disease burden scores following neoadjuvant endocrine therapy in HR-positive, early breast cancer.

Imbruvica plus venetoclax significantly extends PFS in untreated CLL patients compared to chlorambucil plus Gazyva, with 52 months versus 31 months.

Prostate cancer treatments lead to higher long-term complication rates, emphasizing the need for informed decision-making regarding treatment options and side effects.

UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer.

Randy Moss is receiving radiation and chemotherapy after a Whipple procedure for bile duct cancer, a rare condition.

The phase 3 ZEST trial discovered that, with low ctDNA at baseline, the recurrence-free interval is longer for patients with triple-negative breast cancer.

Understanding insurance type is crucial for navigating appeal processes for denied cancer treatment coverage.

The ZEST trial, a phase 3 study on MRD-guided therapy in breast cancer, was terminated early due to low randomization rates.